Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2304 - A Phase 2 Study of Lenvatinib Monotherapy as Second-line Treatment in Unresectable Biliary Tract Cancer: Primary Analysis Results

Date

09 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Hepatobiliary Cancers

Presenters

Masafumi Ikeda

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

M. Ikeda1, T. Sasaki2, C. Morizane3, N. Mizuno4, F. Nagashima5, S. Shimizu6, N. Hayata7, H. Ikezawa7, T. Suzuki7, R. Nakajima7, C. Dutcus8, M. Ueno9

Author affiliations

  • 1 Department Of Hepatobiliary And Pancreatic Oncology, National Cancer Center Hospital East, 2778577 - Kashiwa/JP
  • 2 Hepato-biliary-pancreatic Medicine Department, The Cancer Institute of JFCR, Tokyo/JP
  • 3 Hepatobiliary And Pancreatic Oncology Division, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 4 Department Of Gastroenterology, Aichi Cancer Center Hospital, Nagoya/JP
  • 5 Department Of Internal Medicine, Medical Oncology, School Of Medicine, Kyorin University Hospital, 181-8611 - Tokyo/JP
  • 6 Department Of Gastroenterology, Saitama Cancer Center, Saitama/JP
  • 7 Eisai Co., Ltd., Tokyo/JP
  • 8 Clinical Development, Eisai Inc., Woodcliff Lake/US
  • 9 Hepatobiliary And Pancreatic Oncology, Kanagawa Cancer Center Hospital, Yokohama/JP
More

Resources

Abstract 2304

Background

Lenvatinib (LEN) inhibits vascular endothelial growth factor receptors, fibroblast growth factor receptors, and platelet-derived growth factor receptor-α. These targets have been shown to be expressed in patients (pts) with biliary tract cancer (BTC). A planned interim analysis of this phase 2 study demonstrated preliminary efficacy of LEN 24 mg/d in pts with BTC.

Methods

This open-label phase 2 study conducted in Japan enrolled pts aged ≥ 20 years with a confirmed unresectable BTC, measurable disease per Response Evaluation Criteria in Solid Tumors v1.1, and 1 prior gemcitabine (GEM)-based doublet chemotherapy to receive LEN 24 mg/d. The primary endpoint was objective response rate (ORR). Secondary objectives included disease control rate (DCR), overall survival (OS), progression-free survival (PFS), safety, and pharmacokinetics.

Results

The primary analysis was performed with data on 26 pts. Median age was 64 years and 15 pts (58%) were men. Eastern Cooperative Oncology Group performance status was 0 for 19 pts (73%) and 1 for 7 pts (27%). Six pts (23%) had prior surgery, 20 pts (77%) received prior GEM + cisplatin therapy, and 6 pts (23%) received prior GEM + TS-1. There were 6 pts (23%) with intrahepatic bile duct, 8 (31%) with extrahepatic bile duct, 10 (39%) with gallbladder, and 2 (8%) with ampulla of Vater primary tumor locations. ORR was 12% (90% CI: 3.2–27.2) by both independent and investigator review. DCR was 85% (90% CI, 68.2–94.6) by investigator, and 46% (90% CI, 29.2–63.8) by independent, review. Median PFS was 3.2 months (95% CI, 2.8–7.2) and 1.6 months (95% CI, 1.4–3.2) by investigator and independent review, respectively. Median OS was 7.4 months (95% CI, 4.5–11.3). All pts had treatment-emergent adverse events (TEAEs). Common TEAEs included hypertension, dysphonia, proteinuria, palmar-plantar erythrodysesthesia, decreased appetite, thrombocytopenia, and fatigue. TEAEs led to dose reduction in 20 pts (77%) and discontinuation in 2 pts (8%).

Conclusions

LEN 24 mg/d showed anti-tumor activity in pts with unresectable BTC who had failed GEM-based combination therapy. Toxicities were manageable with dose modifications, reductions, or discontinuations.

Clinical trial identification

NCT02579616

Legal entity responsible for the study

Eisai Inc

Funding

Eisai Inc

Disclosure

M. Ikeda: Honoraria: Novartis, Bayer Yakuhin, BMS, Abbott Jpn, Eisai, Taiho, Ono, Kowa, Eli Lilly Jpn, Chugai, Nippon Kayaku, Daiichi-Sankyo, Yakult; Research: Bayer Yakuhin, Kyowa Hakko Kirin, Yakult, Taiho, Eli Lilly Jpn, Boehringer, Ono, Eisai, AZ. C. Morizane: Honoraria: Pfizer, Novartis, Yakult Honsha, Eli, Nobelpharma, FUJIFILM RI Pharm.; Consulting/advisory: AstraZeneca, Yakult Honsha, Novartis, Taiho Pharm.; Research funding: GSK, Pfizer, Nobelpharma, Eisai, Yakult Honsha, ONO Pharm, Taiho Pharm. N. Mizuno: Research funding: Zeria Pharmaceutical, Taiho Pharmaceutical, Merck Serono, AstraZeneca, NanoCarrier, Eisai, and MSD Honoraria: Taiho Pharmaceutical, Yakult Honsha, Novartis, Pfizer, and Kyowa-Hakko Kirin Speaker\'s bureau: Taiho Pharmaceutical. F. Nagashima: Honoraria: Sanofi, Chugai, Mitsubishi Tanabe, Taiho, Nestle; Research funding: Taiho, Daiichi-Sankyo, Sanofi, Eli Lilly, Sumitomo Dainippon, Eisai, MSD. S. Shimizu: Honoraria: TAIHO, Nippon Kayaku, Novartis. N. Hayata, H. Ikezawa, T. Suzuki: Employment: Eisai Co., Ltd. R. Nakajima: Stock or other ownership: Astellas Pharma, Chion Bioscience. C. Dutcus: Employment: Eisai Inc. M. Ueno: Research funding: ONO Pharma, Baxalta. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.